Tenderwize
Retour à la recherche

Open house drug discount agreements Daridorexant, ATC N05CJ03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Daridorexant, ATC N05CJ03

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume disclosed – cannot assess potential revenue.

Contracts automatically become void if a national/regional discount contract for the same substance is awarded via a fo...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive discount agreements for Daridorexant (ATC N05CJ03)
  • Contract duration: 01.05.2026 to 30.04.2028
Afficher le résumé complet

This is an open-house model (non-procurement) by AOK Bayern for non-exclusive discount agreements on Daridorexant (ATC N05CJ03). Any eligible pharmaceutical company can join at any time before 2028-03-03. Contracts run from 2026-05-01 to 2028-04-30. No estimated value is disclosed. The procedure is not subject to procurement law; it is a voluntary open-house scheme. Interested companies must request access to documents via the DTVP portal and submit a signed contract and self-declaration of reliability either in paper (two originals) or electronically with a qualified electronic signature. The contract language is German. Automatic termination if a national discount contract for the same substance is awarded.

Risques

No estimated value or volume disclosed – cannot assess potential revenue.

Contracts automatically become void if a national/regional discount contract for the same substance is awarded via a fo...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies eligible

Administrative

  • Must submit signed contract, annex (listing of medicinal products), and self-declaration of reliability
  • Submission: either paper (two originals) or electronically with qualified electronic signature (QES)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Daridorexant, ATC N05CJ03

Non-exclusive framework for discount agreements on Daridorexant (ATC N05CJ03) with any eligible pharmaceutical company in Bavaria (Germany). No lot-specific values or award criteria.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 03, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
178897-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30